Subscribe   RSS Contact Us

Kamp Commentary: Pricing Issues Take Center Stage in D.C.

May 23, 2017 — By Coalition for Healthcare Communication Executive Director John Kamp Participants at last week’s Coalition for Healthcare ... read more

Califf Calls for Off-label Promotion Code of Ethics

May 18, 2017 – At this week’s information-packed Coalition for Healthcare Communication’s Rising Leaders Conference, keynote speaker and former FDA ... read more

The Marketing Implications of Tax Reform

By John Kamp, Coalition for Healthcare Communication Executive Director May 11, 2017 – Although no one seems to like the ... read more

Gottlieb Vote Headed to Full Senate

May 1, 2017 – Having cleared the Senate Committee on Health, Education, Labor and Pensions (HELP) with a 14-9 vote ... read more

What Medical Marketers Can Expect from President Trump, Republican-led Congress

April 24, 2017 – There is no doubt that the Trump administration is likely to change health policy, but the ... read more

Kamp: Three Ways Congress Could Suppress DTC or All Medical Marketing

Coalition Commentary by Executive Director John Kamp April 17, 2017 — Agencies, media and clients all need to watch closely ... read more

States Make Moves to Ease, Restrict Medical Communications

March 31, 2017 – With Congress in a seemingly permanent state of gridlock, individual states are taking actions that may ... read more

Previous Next

Kamp To Moderate DIA Webinar on Caronia Case Implications

Dec. 18, 2012 – Whether the U.S. Court of Appeals for the Second Circuit’s decision in U.S. v Caronia will reset the legal boundaries between the FDA and pharmaceutical manufacturers’ right to disseminate off-label information about approved drug products will be the topic of discussion at a Jan. 23, 2013, Drug Information Association Webinar moderated by Executive Director of the Coalition for Healthcare Communication John Kamp.

The Webinar, to be held 11 a.m. to 12:30 p.m., will encourage speakers Bert Rein, partner, Wiley Rein, Alan Bennett, partner, Ropes and Gray and Mit Spears, General

Counsel, PhRMA (invited), to discuss the Caronia decision, which overturned the criminal conviction of pharmaceutical sales representative Alfred Caronia and may be the most significant commercial free speech decision issued by a federal appeals court in many years.

Legal, regulatory and industry experts will present the facts of the case, discuss possible appeals, and answer questions about how the decision will affect settlements on “false claims” acts prosecutions. The speakers also will cover possible FDA rules on professional and consumer advertising, including social media, and address off-label marketing using comparative effectiveness and economic studies.

For more information, contact DIA at: http://www.diahome.org/en/Meetings-and-Training/Find-Meetings-and-Training/Meeting-Details.aspx?ProductID=2131873&EventType=Webinar